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served that stem cells taken from colorectal cancer patients could be evaluated for gene expressions of CD44 and CD133 and that patients with tumors harboring higher levels of both CD44 and CD133 had a higher risk of developing early liver metastases. On the contrary, in a study by Dallas et al. [2] , cells that were engineered to be knock-down for CD44 expression had almost a 10-fold increase in metastatic potential in both the liver and the lungs. In addition to that, CD44 negative cells exhibited a greater "mechanical compliance", a property that is considered crucial in the process of extravasation and migration through the blood stream. These findings were similar with Hong et al. [3] 's recent findings that low levels of CD44 were relevant for increased tumor relapse and short disease-free survival in colon cancer patients. A possible explanation for this conflicting data could be that genetic and epigenetic differences have impacts on the expressions of CSC surface markers.
Giampieri et al. [4] assessed the role of colorectal CSC markers (ALCAM, CD133, CD24, LGR5, SOX2, and ALDH1A1) in determining the clinical outcomes for stage-III colon-cancer patients receiving adjuvant chemotherapy. They concluded that patients expressing high ALCAM levels may require more intensive treatment and possibly a change to a different treatment option.
Still many questions related to CSCs remain to be solved. Growth factors, such as epidermal growth factor (EGF) and vascular endothelial growth factor, and cytokines, such as transforming growth factor-β, tumor necrosis factor-α, and interluekin-6, produced by a microenvironment can revert differentiated cells to a more stem-cell-like state and the EGF signaling pathway may regulates intestinal epithelial cell and stem/progenitor cell growth and differentiation. However, little knowledge exists concerning the role of growth factors in mediating proliferation and self-renewal of colon CSCs. CSC numbers have been shown to be increased after chemotherapy or irradiation for the treatment of CRC [5] . Quiescent CSCs are spared by cytotoxic therapies, which usually result in a relative increase in tumor stem-cell content due to the selective survival of the CSC fraction. Moreover, after initially targeting proliferating CSCs, multiple cycles of chemotherapy may promote CSC proliferation and self-renewal. Besides chemotherapy, tar-geted therapies that partially or totally ablate the CSC pool may have to face the problem of CSC regeneration due to the ability of non-stem cells to recreate CSCs. In an even worse scenario, targeted therapies may elicit a reactive response resulting in the resurgence of more aggressive tumors. A possible solution for avoiding posttherapy regeneration of CSCs would be to combine CSC-targeted therapies with drugs that inhibit either the microenvironmental or the epigenetic mechanisms responsible for the reprogramming of transit-amplifying progenitors into CSCs. Interfering with tumor cell plasticity may, therefore, offer new tools to support the activity of both conventional and targeted anticancer drugs.
Further extensive studies are needed to elucidate whether these intestinal stem-cell markers can be used as predictive and prognostic biomarkers in a clinical setting. In addition, emerging CSCeliminating therapies should target molecular pathways in CSCs and mediators, as well as in their surrounding microenvironments.
